Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repligen Corp (NQ: RGEN )

143.10 +1.34 (+0.95%)
Streaming Delayed Price Updated: 10:11 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repligen Corp

< Previous 1 2 3 4 5 6 Next >
Earnings Outlook For Repligen
Repligen (NASDAQ:RGEN) announces its next round of earnings this Tuesday, July 27. Here is Benzinga's everything-that-matters guide for this Tuesday's Q2 earnings announcement.... 
Via Benzinga
3 Healthcare Stocks to Buy and Hold for the Next 10 Years
Don't overthink it -- buy companies with excellent financials and a long runway for growth. 
Via The Motley Fool
Repligen To Buy Polymem For An Undisclosed Sum
Repligen Corporation (NASDAQ: RGEN) has agreed to acquire France-based Polymem S.A., a provider of hollow fiber membranes and modules. "The acquisition... 
Via Benzinga
Repligen Joins Elite List Of Stocks With 95-Plus Composite Rating
The new score means Repligen is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria. 
Via Investor's Business Daily
Exposures COVID-19
Repligen Corp (RGEN) Q1 2021 Earnings Call Transcript
RGEN earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Repligen Earnings Double As Sales Growth Accelerates; RGEN Stock Nears Buy Point
Repligen earnings shot up 113% in Q1 with sales growth accelerating to 88%. The biotech raised full-year guidance. RGEN stock rose, nearing a buy point. 
Via Investor's Business Daily
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Dow Jones Hits High As Metals, Miners, Fertilizers Thrive, But Growth Stocks Slump; Jobs Report Stunningly Weak
The Dow hit highs but growth stocks slumped, despite a Friday bounce on weak jobs gains. Miners, metals, fertilizers thrived. 
Via Investor's Business Daily
Topics Economy Intellectual Property Stocks
Exposures COVID-19 Intellectual Property Interest Rates
Repligen: Q1 Earnings Insights
Shares of Repligen (NASDAQ:RGEN) moved higher by 7.5% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 112.50% over... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7... 
Via Benzinga
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Earnings Scheduled For May 4, 2021
Companies Reporting Before The Bell • Lancaster Colony (NASDAQ:LANC) is likely to report quarterly earnings at $1.24 per share on revenue of $340.02 million. •... 
Via Benzinga
Repligen Stock Gets Relative Strength Rating Upgrade With Earnings Due
A Relative Strength Rating upgrade for Repligen shows improving technical performance. Will it continue? 
Via Investor's Business Daily
Medical Device Maker Quanterix Sees Relative Strength Rating Rise To 86
On Tuesday, Quanterix stock hit an important technical milestone, with its Relative Strength (RS) Rating rising into to 86, up from 80 the day before. 
Via Investor's Business Daily
Align Technology Nears Buy Point With Earnings Due
Align Technology is near a possible buy zone ahead of its next quarterly earnings report, expected on or around April 28. 
Via Investor's Business Daily
Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member. 
Via Investor's Business Daily
Cancer Therapy Novocure Stock Flashes Renewed Technical Strength
Novocure stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 67 to 92. 
Via Investor's Business Daily
10 Biggest Price Target Changes For Monday
Canaccord Genuity raised the price target on Tesla, Inc. (NASDAQ: TSLA) from $419 to $1071. Tesla shares rose 1.5% to $687.13 in pre-market trading. Keybanc lowered the price... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS